Browse EX-10 agreements

LEAR CORPORATION
2019 LONG-TERM STOCK INCENTIVE PLAN

(As Amended and Restated as of May 14, 2026)

Article 1.    Establishment, Objectives and Duration

1.1    Establishment of the Plan.Lear Corporation, a Delaware corporation (the “Company”), hereby establishes thisLear Corporation 2019 Long-Term Stock Incentive Plan, as set forth in this document and as may be amended or amended and restated from time to time (the “Plan”). Capitalized terms used but not otherwise defined herein will have the meanings given to them in Article 2. The Plan permits the grant of Nonqualified Stock Options, Incentive Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Units, Restricted Stock Units, Performance Shares, Performance Units and other cash and equity incentive Awards. The Plan was first approved by the Committee on March 26, 2019, and by the Company’s shareholders on May 16, 2019 (the “Effective Date”). It was subsequently amended and restated on May 14, 2023, and the Company’s shareholders approved an increase in the number of Shares that could be awarded under the Plan.

…

This Promissory Note (this “Note”) and the securities issuable upon conversion of this Note pursuant to the terms hereof have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and neither this note, such securities nor any interest therein may be offered, sold, transferred, pledged or otherwise disposed of except pursuant to an effective registration statement under such act or such laws or an exemption from registration under such act and such laws which, in the opinion of counsel for maker, is available.

** **

CONVERTIBLE PROMISSORY NOTE

** **

Principal Amount: $25,000	Dated as of May 21, 2026

…

This Promissory Note (this “Note”) and the securities issuable upon conversion of this Note pursuant to the terms hereof have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and neither this note, such securities nor any interest therein may be offered, sold, transferred, pledged or otherwise disposed of except pursuant to an effective registration statement under such act or such laws or an exemption from registration under such act and such laws which, in the opinion of counsel for maker, is available.

** **

CONVERTIBLE PROMISSORY NOTE

Principal Amount: $25,000	Dated as of July 29, 2026

** **

…

This Promissory Note (this “Note”) and the securities issuable upon conversion of this Note pursuant to the terms hereof have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and neither this note, such securities nor any interest therein may be offered, sold, transferred, pledged or otherwise disposed of except pursuant to an effective registration statement under such act or such laws or an exemption from registration under such act and such laws which, in the opinion of counsel for maker, is available.

** **

CONVERTIBLE PROMISSORY NOTE

** **

Principal Amount: $25,000	Dated as of May 21, 2026

…

This Promissory Note (this “Note”) and the securities issuable upon conversion of this Note pursuant to the terms hereof have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws and neither this note, such securities nor any interest therein may be offered, sold, transferred, pledged or otherwise disposed of except pursuant to an effective registration statement under such act or such laws or an exemption from registration under such act and such laws which, in the opinion of counsel for maker, is available.

** **

CONVERTIBLE PROMISSORY NOTE

Principal Amount: $25,000	Dated as of July 29, 2026

** **

…

VISTAGEN THERAPEUTICS, INC.

INDEMNIFICATION AGREEMENT

THIS AGREEMENT is entered into, effective as of July 29, 2026 between Vistagen Therapeutics, Inc., a Nevada corporation (the "Company"), and Douglas J. Williamson, M.D. (“Indemnitee”).

WHEREAS, it is essential to the Company to retain and attract as directors and officers the most capable persons available;

WHEREAS, Indemnitee is a director of the Company;

WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims currently being asserted against directors and officers of corporations; and

…

Execution Version

AMENDMENT NO. 10, dated as of May 28, 2026 (this “Amendment”), to First Lien Credit Agreement, dated as of March 5, 2019 (as amended by the Technical Amendment, dated as of May 13, 2019, as supplemented by the Joinder Agreement, dated as of September 30, 2019, as amended by Amendment No. 1, dated as of January 30, 2020, as amended by Joinder Agreement and Amendment No. 2, dated as of June 30, 2020, as amended by Joinder Agreement and Amendment No. 3, dated as of October 7, 2020,as amended by Amendment No. 4, dated as of April 8, 2021, as amended by Joinder Agreement and Amendment No. 5, dated as of April 16, 2021, as amended by Joinder Agreement and Amendment No. 6, dated as of June 30, 2023, as amended by Joinder Agreement and Amendment No. 7, dated as of February 21, 2024, as amended by Joinder Agreement and Amendment No. 8, dated as of September 17, 2024, as amended by Amendment No. 9, dated as of December 11, 2024, and as otherwise amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”; and the C

…

May 20, 2026

Amit Muni

c/o Cohen & Steers, Inc.

1166 Avenue of the Americas

New York, New York 10036

Dear Amit,

We are pleased to offer you employment as an Executive Vice President, Chief Financial Officer at Cohen & Steers, Inc. (“Cohen & Steers”, or the “Company”) reporting to Joseph Harvey, Chief Executive Officer to commence no later than June 8, 2026 (the “Start Date”).

Base Salary and Term. You will be paid a salary at an annual rate of $450,000, less applicable deductions and in accordance with Cohen & Steers’ regular payroll practices, to compensate you for all hours you work, regardless of whether more or less than 40 in a regularly scheduled workweek. Salaries are reviewed annually, and adjustments (if any) will be based on your performance, prevailing economic conditions, and the firm’s profitability.

You will be paid on a semi-monthly basis on the 15th and the last business day of the month unless this regular payday occurs on a Saturday, Sunday, or holiday, in which case you will be paid on the last working day prior to the regular payday.

…

STANDBY EQUITY PURCHASE AGREEMENT

** **

THIS STANDBY EQUITY PURCHASE AGREEMENT (this “Agreement”) dated as of July 30, 2026 is made by and between Javelin Global Investors Limited, a British Virgin Islands company (the “Investor”), and WF Holding Limited, a Cayman Islands exempted company (the “Company”).

** **

BACKGROUND

** **

WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Company shall have the right to issue and sell to the Investor, from time to time as provided herein, and the Investor shall purchase from the Company, up to $30,000,000 of the Company’s ordinary shares, $0.00025 par value (the “Ordinary Shares”);

** **

WHEREAS, the Ordinary Shares are listed for trading on the Nasdaq Capital Market under the symbol “WFF;” and

** **

…

**PLACEMENT AGENCY AGREEMENT **

July 30, 2026

Univest Securities, LLC

75 Rockefeller Plaza, Suite 25A

New York, NY 10019

Ladies and Gentlemen:

Subject to the terms and conditions of this agreement (this “Agreement”) and the Transaction Documents (as defined below), WF Holding Limited, an exempted company incorporated in the Cayman Islands (the “Company”), hereby agrees to establish an equity line of credit financing facility (the “ELOC”) pursuant to which the Company may, in its sole discretion from time to time during the commitment period specified in the applicable Transaction Documents (the “Commitment Period”), direct one or more accredited and/or institutional investors (each, an “Investor” and collectively, the “Investors”) to purchase from the Company up to approximately $30,000,000 in the aggregate of ordinary shares, par value $0.00025 per share, of the Company (the “Ordinary Shares”), through Univest Securities, LLC, as exclusive placement agent (the “Placement Agent”). The offer and sale of the Securities (as defined below) will be made pursuant to the Company’s eff

…

CO-DIAGNOSTICS, INC.

---

2401 S. Foothill Drive, Suite D

Salt Lake City, Utah 84109

July 30, 2026

To the Holder of May 2026 Common Stock Purchase Warrants

Re:	Inducement Offer to Exercise Existing Common Stock Purchase Warrants

Dear Holder:

CO-DIAGNOSTICS, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise the warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), currently held by you (the “Holder,” “you” or similar terminology) and issued to you on May 21, 2026 (the “May 2026 Warrants”). The number of shares (the “Warrant Shares”) underlying May 2026 Warrants that the Holder agrees to exercise (the “Existing Warrants”) on terms set forth herein and as set forth on the signature page hereto are registered pursuant to the registration statement on Form S-3 (File No. 333- 296312) (the “Registration Statement”). T

…

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 29, 2026 is entered into by and among Beyond Air, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

WHEREAS:

…